Other equities analysts have also issued reports about the stock. Chardan Capital reaffirmed a buy rating and set a $100.00 target price on shares of Spark Therapeutics in a research report on Friday, October 13th. BMO Capital Markets set a $89.00 price objective on shares of Spark Therapeutics and gave the company a buy rating in a report on Tuesday, October 10th. Cowen reissued a buy rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Jefferies Group reissued a buy rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Cantor Fitzgerald reissued a buy rating and set a $105.00 price objective (up from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $90.36.
Shares of Spark Therapeutics (ONCE) traded up $0.85 during trading hours on Thursday, hitting $70.56. 526,100 shares of the stock were exchanged, compared to its average volume of 397,681. Spark Therapeutics has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.
In related news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the business’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the completion of the transaction, the director now directly owns 3,928,707 shares in the company, valued at $332,486,473.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $82.50, for a total transaction of $495,000.00. Following the transaction, the insider now owns 6,000 shares of the company’s stock, valued at $495,000. The disclosure for this sale can be found here. Insiders have sold 1,074,809 shares of company stock valued at $90,304,385 over the last quarter. Insiders own 7.30% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Spark Therapeutics by 20.3% in the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after buying an additional 10,544 shares in the last quarter. Balyasny Asset Management LLC increased its holdings in Spark Therapeutics by 104.8% in the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after buying an additional 30,400 shares in the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Spark Therapeutics by 103.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 55,000 shares of the biotechnology company’s stock valued at $4,904,000 after buying an additional 28,000 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new position in Spark Therapeutics in the second quarter valued at $30,848,000. Institutional investors own 94.94% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/08/spark-therapeutics-once-buy-rating-reaffirmed-at-raymond-james-financial.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.